CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) is an increasing cause of both morbidity and mortality worldwide. Despite major efforts to develop effective treatment, current treatment regimens can at best delay disease progression. COPD is usually defined as a chronic inflammatory condition (40) , but the mechanisms of COPD pathogenesis have not yet been fully elucidated.
Macrophage migration inhibitory factor (MIF) has been recognized as a central immunological mediator since the early 1990s (4, 5, 43) . MIF has been shown to be involved in a wide range of diseases such as cancer (11, 24) , atherosclerosis (46) , diabetes (34) , and several inflammatory conditions (4, 19) . In the lungs, MIF can be found in macrophages, lymphocytes, eosinophils, and the capillary endothelium (4, 8, 22, 31, 45) . Increased MIF levels have been measured in both bronchial alveolar lavage (31) and serum (45) in patients with asthma. Raised MIF values has also been observed in acute respiratory distress syndrome (ARDS) (22) , obstructive sleep apnea (14) , and idiopathic pulmonary fibrosis (2) .
MIF induces a wide range of effects by different modes of action. Its function is mostly proinflammatory with chemokinelike properties (4) via binding and activation of CD74 receptors found in a variety of tissues, initiating cytokine release and cell proliferation (23) . MIF has a significant role in the innate immune defense against acute viral and bacterial infection (20, 30) , tuberculosis (12) , and protozoan diseases (6) . On the other hand, MIF may also contribute to the exaggerated inflammation observed with sepsis and ARDS (10, 22) . In addition to these functions, MIF has a unique feature by its induction by glucocorticoids, in which MIF is one of a few mediators with the ability to antagonize the anti-inflammatory effect of glucocorticoids (7) .
It would appear likely that MIF could be an interesting target in COPD; a chronic inflammatory disease of the lungs in which the innate immune system seems dysregulated, and in which treatment by inhaled glucocorticoids has been disappointing. Yet only a few studies have examined the relationship between MIF and COPD. Contrary to the conditions listed above, some studies have associated COPD with decreased values of MIF (15, 36) , although two more recent studies indicated the opposite (25, 32) . COPD exacerbations are often triggered by infections in which MIF potentially mediates both beneficial (antimicrobial) and harmful (sustained or overwhelming inflammation) effects. Yet prior studies have examined MIF levels only during stable COPD, and the potential role of MIF in COPD exacerbations has thus not been assessed.
The present study aimed to measure levels of MIF in stable COPD and during acute COPD exacerbations, and to examine the relationship between the levels of MIF and important COPD characteristics using data from a large patient-control cohort study in western Norway.
MATERIALS AND METHODS
Study population. The Bergen COPD Cohort Study (BCCS) included 433 subjects with COPD and 325 healthy individuals who served as controls between 2006 and 2009 (13, 27) . All subjects were 40 to 76 yr of age at inclusion. All patients with COPD had a clinical diagnosis of COPD as evaluated by the study physician, a smoking history of more than 10 pack-years, a postbronchodilation FEV1/FVC ratio of Ͻ0.7, and an FEV1 of less than 80%. Patients with cancer within 5 yr before inclusion, lung disorders other than COPD including asthma, active inflammatory disease other than COPD, or exacerbations during 4 wk before inclusion were not included, but the latter category could be rescreened and included later.
Of the 433 patients with COPD, 356 residing in our hospital district were also included in the Bergen COPD Exacerbation Study (BCES). These patients were given detailed instructions on COPD exacerbation criteria (see APPENDIX) on a laminated card fit for a wallet, and when their symptoms met the criteria they were asked to contact a study nurse by telephone. Upon contact, they were directed to either immediate hospitalization or to visit the outpatient clinic with a study physician the next working day. Blood samples were taken from individuals no later than the first working day after telephone contact. Samples during COPD exacerbations were drawn at least once for 149 patients. Details on BCES sampling have been previously published (39) .
Informed consent was obtained from all participants in the studies. The studies were approved by the Regional Committee for Medical and Health Research Ethics, region west (REK-Vest, case number 165.05).
Data collection. All patients and controls were examined by a study physician at the point of inclusion in the study, which included a clinical interview to assess respiratory symptoms, smoking history, comorbidities, and medication. All patients and individuals in the control groups performed spirometry before and after bronchodilation with 0.4 mg of salbutamol using a Viasys Masterscope. Patients with COPD were categorized according to 2007 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, the current guidelines at the time of inclusion.
Body composition was assessed with bioelectrical impedance measurements. Cachexia was defined as a fat-free mass index less than 17 kg/m 2 and 14 kg/m 2 in men and women, respectively (41) , which corresponds to the lower 95% confidence limit in a normal population (38) . Obesity was defined as a fat mass index of more than 9.3 kg/m 2 in men or more than 13.5 kg/m 2 in women (38) . Emphysema was assessed by computed tomography, defined as having more than 10% of emphysematous lung tissue, specified as tissue density of less than Ϫ950 HU. Chronic bronchitis was defined as having cough for more than 3 mo the year before inclusion. Data on emphysema and chronic bronchitis were not available for 49 and 11 patients, respectively.
Laboratory measurements. Serum samples were coagulated at room temperature for 30 -45 min, followed by centrifugation at 2,500 g for 15 min at 4°C. The serum was aliquoted and stored at Ϫ80°C. Serum levels of MIF were measured using enzyme immunoassays from R&D Systems (Minneapolis, MN). The inter-and intra-assay coefficients of variation were less than 10%. Serum sampling failed for 9 patients and 6 controls.
Statistical analyses. The distribution of MIF serum levels was not normal, so nonparametric tests were used for evaluating bivariable associations. For multivariable analyses, MIF levels were loge transformed and modeled as the outcome variable. The coefficients were exponentiated after analysis and shown as geometric mean ratios. For comparison between patients with COPD and control individuals, a linear regression model was fitted that included sex, age, body composition, smoking status (explored both as a categorical variable and as pack-years smoked), and CCS. A similar model was used when evaluating MIF levels in patients with stable COPD, also including COPD-specific variables: GOLD category, number of exacerbations the last year, use of inhaled steroids, presence of emphysema, and chronic bronchitis. Variation inflation factor analysis was used to evaluate the potential colinearity of variables in the model (29a). For comparison of MIF levels between stable disease and exacerbation, a Wilcoxon equality test on matched data was performed, comparing paired samples in 146 patients. MIF levels at COPD exacerbation were evaluated and adjusted for all variables mentioned above, and in addition, oral steroids, exacerbation severity, and respiratory symptoms (see APPENDIX) with both bivariable and multivariable regression. Stata 12.1 (Stata Corp, College Station, TX) was used for statistical analyses.
RESULTS
The baseline characteristics of the study population are presented in Table 1 . The patients with COPD were older, more likely to experience cachexia or obesity, had different smoking habits, and more comorbidity than subjects without COPD.
Comparison of MIF levels between patients with COPD and controls. Median MIF (interquartile range, IQR) concentration was significantly elevated among the 424 patients with COPD compared with the 319 controls, at 20.1 ng/ml (13.5-30.9) vs. 14.9 ng/ml (11.1-21.6), respectively (P Ͻ 0.01, Wilcoxon rank sum test). Bivariable associations between MIF and the demographic covariates in patients with COPD and controls are presented in Table 2 , in addition to COPD-specific variables in patients only. MIF levels were higher in men, although they reached statistical significance only in patients with COPD. Patients with COPD and obesity or higher comorbidity score had significantly higher MIF levels ( Table 2 ).
An adjusted analysis of MIF levels in patients with COPD vs. those in the control group is presented in Table 3 . A geometric mean ratio means that patients with COPD had an MIF level 1.30 times higher than those in the control group, adjusted for all other variables in Table 3 . Thus patients with COPD had significant higher levels of MIF than those in the control group, whereas cachexia was associated with lower MIF levels. Age and comorbidity (CCS) did not affect systemic levels of MIF (Table 3) , and neither did smoking, either modeled as a categorical variable or with pack-years smoked as COPD not using inhaled glucocorticoids showed they also had significantly higher MIF levels than those in the control group (geometric mean ratio 1.19, P ϭ 0.047). MIF levels related to COPD characteristics. The potential associations between COPD characteristics and systemic levels of MIF among patients with COPD at the stable phase, after adjustment for covariables are shown in Table 4 . We found a trend toward decreasing MIF levels in higher GOLD categories, but it was not statistically significant. We also evaluated patients according to the GOLD 2011 classification (GOLD A-D), but found no significant association (data not shown). Nor was there any significant association between MIF levels and body composition; smoking; comorbidity (CCS); or between MIF and the COPD-specific variables exacerbation frequency, chronic bronchitis, or CT-evaluated emphysema. Patients using inhaled steroids tended to have higher levels of MIF (Table 4) . Inclusion of the emphysema variable reduced the sample size of the regression model because of missing data for 49 patients. With the exclusion of the emphysema variable, the coefficient for inhaled steroids was the same (1.15), but the P value changed to 0.04, suggesting that inhaled steroid use indeed may affect MIF levels. There was no evidence of colinearity between variables in the models.
MIF levels during COPD exacerbations. Among the 146 patients with MIF measurements both in the stable phase and during a COPD exacerbation, median (IQR) MIF level during exacerbations, 23.3 ng/ml (14.1-43.5), was significantly higher than median level at stable COPD in the same 146 patients, 19.4 ng/ml (12.4 -31.2), P Ͻ 0.01 (Fig. 1) . Table 5 shows MIF levels during exacerbation by several COPDspecific variables. No significant associations were found between levels of MIF during exacerbations and these variables, either in bivariate (Table 5 ) or in multivariable analysis (data not shown).
DISCUSSION
This study showed that serum levels of MIF are significantly elevated in patients with stable-phase COPD compared with healthy control individuals. Furthermore, we observed an additional increase in MIF levels during COPD exacerbations, and we identified a potential association between increased MIF and the use of inhaled glucocorticoids.
We used data from a large cohort study in western Norway. The main strength of this study was its large number of participants (n ϭ 743), allowing multivariable regression analysis with adjustment for several important covariables. Our study also included longitudinal follow-up for a subcohort of the patients, with assessment of levels of MIF during COPD exacerbations.
A few shortcomings to our study should be mentioned. First, the COPD cohort and the control group were unmatched, and the COPD patients were, by comparison, significantly older, more cachectic or obese, had different smoking habits, and more comorbidity. Although all these factors were evaluated in the multiple regression analyses, selection bias cannot be fully excluded. Second, there is the potential for misclassification between COPD and asthma. Several measures were taken to ensure as low a misclassification as possible: to be included, patients were classified according to GOLD criteria in categories II-IV, had smoked more than 10 pack-years, were older than 40 yr of age, and most importantly, only patients were included whom the study physician deemed to have COPD and not asthma on the basis of a complete medical history and all available test results. Furthermore, there were no differences between MIF levels in the 83 patients with COPD with a positive reversibility test (defined as increase in FEV 1 Ն200 ml and Ն12%) compared with the 341 patients without COPD (21.4 ng/ml vs. 19.9 ng/ml, respectively) (P ϭ 0.27). Third, the degree to which serum levels of MIF reflect lung-specific or systemic inflammation is not known. Fourth, this is a crosssectional analysis, and causality cannot be determined. Fifth, because of a lack of power analysis, the study may have been underpowered to verify significant findings only observed as trends in our material. Finally, a replication cohort for validation of our findings would strengthen our study.
Our findings are in accordance with the observation of increased MIF levels in a range of inflammatory conditions (19) , but they oppose two earlier studies demonstrating a decrease in MIF levels in patients with COPD (15, 36) . Sauler et al. (36) found lower plasma MIF levels in 32 patients with COPD compared with 40 individuals in the control group, all older than 65 yr, adjusting for sex, age, and smoking. Fallica et al. (15) found decreased serum MIF levels in 32 patients with COPD compared with 18 nonsmoking control individuals (unadjusted values). We believe our study gives a more representative view of MIF levels in patients with COPD, both because of its size and additional adjustment for important covariates such as body composition, comorbidities (CCS), and use of inhaled steroids. More recently, Milara et al. (25) analyzed MIF mRNA expression in peripheral neutrophils and found an increase in 15 patients with COPD compared with 15 control individuals, which is in accordance with our findings (25) . Russell et al. (32) found increased MIF in sputum and bronchial alveolar lavage, but not serum, in 25 patients with COPD compared with nonsmoking control individuals (32) .
The significance of increased MIF levels in COPD is not completely clear. The increased serum MIF levels could represent spillover from localized lung inflammation, but they may also be a result of systemic inflammation with either central or other peripheral sources. Its proinflammatory effects in peripheral tissues are proposed to be mediated via stimulation of the CD74 receptor, further activating the extracellularsignal-regulated kinase 1/2-mitogen-activated protein kinase (ERK1/2-MAPK) cascade, promoting release of cytokines and prostaglandins, and preventing apoptosis of inflammatory cells via p53 inhibition (16, 26) . In COPD there are several potential triggers of MIF release; COPD is associated with higher levels of several proinflammatory cytokines both in peripheral blood and in the lungs (21) . Patients with COPD may also have an altered lung microbiome, both in microbial load and in diversity (28) , which might stimulate MIF release. Smoking is CT, computed tomography. *Adjusted also for sex, age (continuous variable), body composition, smoking habits, and Charlson Comorbidity Score.
†Exponentiated coefficients presented as geometric mean (GM) ratios. another possible trigger of inflammation, although we found no difference in MIF comparing current vs. former smokers. There are several potential explanations for the additional increase of MIF levels during COPD exacerbations. Exacerbations are associated with an increase in both local and systemic inflammation, and with bacterial or viral infection (21, 42) , all potential triggers of MIF release. Furthermore, COPD exacerbations are often treated with glucocorticoids, which may further increase MIF levels (7). However, unlike the findings in stable COPD, we found no significant association between oral or inhaled glucocorticoids and MIF levels at exacerbation, suggesting that the MIF-enhancing effect of microbial product is stronger than the effect of glucocorticoids.
A major problem in the treatment of COPD is the lack of effective medication. Although some patients may be classified as having "overlap-syndrome" with features of both asthma and COPD, the majority of patients with COPD experience limited effect from either inhaled or systemic glucocorticoids (3) . Glucocorticoids can stimulate immunological cells via the intracellular glucocorticoid receptor, inducing expression of MAPK phosphatase 1 (MKP-1), a known inhibitor of the ERK1/2-MAPK cascade (17) . MIF is believed to inhibit the glucocorticoid effects by suppressing MKP-1, thereby counterbalancing the anti-inflammatory effect. We found a likely association with the use of inhaled glucocorticoids and increased MIF values. The induction of MIF release by glucocorticoids, both central and peripheral, is regarded as an important characteristic of MIF (7, 17) . This effect may only partly explain the elevated MIF levels in COPD, because steroid-naive patients also had significantly higher levels than individuals in the control group, albeit to a lower extent. Nonetheless, it is tempting to hypothesize that the high levels of MIF in COPD associated with the use of inhaled glucocorticoids could contribute to the lack of effects of these medications in patients with COPD.
Although overexpression of MIF is important in the defense against infection, there is mounting evidence that it contributes to excessive inflammation in various conditions (9, 10, 14, 19, 22) . Still, it is not certain whether overexpression of MIF has a negative effect on the disease progression of COPD; some advocate that its antiapoptotic effect may be beneficial against development of emphysema (15, 36), and it may have a protective role against oxidative stress (37) Our knowledge of MIF has increased considerably the last two decades after its rediscovery in the 1990s. MIF is now acknowledged as an upstream regulator of the immune response, yet many of its other attributes have not yet been uncovered. MIF is linked to a wide range of inflammatory conditions, and our study expands this list to include COPD. We demonstrate that MIF is independently associated with COPD, and we also show a possible role for MIF in COPD exacerbations. Furthermore, of particular clinical interest is the possible link between high MIF levels and glucocorticoid resistance in COPD. Further research needs to occur to define its role in COPD; in particular, longitudinal studies on the long-term effects of sustained high expression of MIF, and also the effects of different MIF alleles.
APPENDIX

1) COPD exacerbation criteria
A COPD exacerbation was defined as 2 major or 1 majorϩ1 minor. Major:
• Increased dyspnea • Increased sputum production • Increased sputum purulence Minor:
• Rhinitis 
